CN1500095B - 神经胚活素的多聚体偶联物及其应用方法 - Google Patents

神经胚活素的多聚体偶联物及其应用方法 Download PDF

Info

Publication number
CN1500095B
CN1500095B CN028077539A CN02807753A CN1500095B CN 1500095 B CN1500095 B CN 1500095B CN 028077539 A CN028077539 A CN 028077539A CN 02807753 A CN02807753 A CN 02807753A CN 1500095 B CN1500095 B CN 1500095B
Authority
CN
China
Prior art keywords
polypeptide
seq
neublastin
amino acid
nbn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN028077539A
Other languages
English (en)
Chinese (zh)
Other versions
CN1500095A (zh
Inventor
黛娜·W·Y·萨
R·布莱克·佩平斯基
葆拉·A·博杰克-斯乔丁
斯蒂芬·S·米勒
安东尼·罗索曼多
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Than Ao Gen Ma Co
Original Assignee
Biogen Inc
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc, Biogen Idec MA Inc filed Critical Biogen Inc
Publication of CN1500095A publication Critical patent/CN1500095A/zh
Application granted granted Critical
Publication of CN1500095B publication Critical patent/CN1500095B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
CN028077539A 2001-02-01 2002-01-25 神经胚活素的多聚体偶联物及其应用方法 Expired - Fee Related CN1500095B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26607101P 2001-02-01 2001-02-01
US60/266,071 2001-02-01
PCT/US2002/002319 WO2002060929A2 (en) 2001-02-01 2002-01-25 Polymer conjugates of neublastin and methods of using same

Publications (2)

Publication Number Publication Date
CN1500095A CN1500095A (zh) 2004-05-26
CN1500095B true CN1500095B (zh) 2010-06-16

Family

ID=23013042

Family Applications (1)

Application Number Title Priority Date Filing Date
CN028077539A Expired - Fee Related CN1500095B (zh) 2001-02-01 2002-01-25 神经胚活素的多聚体偶联物及其应用方法

Country Status (35)

Country Link
EP (2) EP1862475A1 (enExample)
JP (2) JP4259868B2 (enExample)
KR (2) KR100872807B1 (enExample)
CN (1) CN1500095B (enExample)
AR (1) AR035077A1 (enExample)
AT (1) ATE365748T1 (enExample)
AU (1) AU2002247037B2 (enExample)
BG (1) BG66393B1 (enExample)
BR (1) BR0206852A (enExample)
CA (1) CA2436407C (enExample)
CY (1) CY1106886T1 (enExample)
CZ (1) CZ20032080A3 (enExample)
DE (1) DE60220879T2 (enExample)
DK (1) DK1355936T3 (enExample)
EA (1) EA009771B1 (enExample)
EE (1) EE05537B1 (enExample)
ES (1) ES2289091T3 (enExample)
GE (1) GEP20063916B (enExample)
HU (1) HU228973B1 (enExample)
IL (2) IL156941A0 (enExample)
IS (1) IS2867B (enExample)
MX (1) MXPA03006805A (enExample)
MY (1) MY143685A (enExample)
NO (1) NO332150B1 (enExample)
NZ (1) NZ527863A (enExample)
PL (1) PL211162B1 (enExample)
PT (1) PT1355936E (enExample)
RS (1) RS50857B (enExample)
SG (1) SG149685A1 (enExample)
SI (1) SI1355936T1 (enExample)
SK (1) SK288123B6 (enExample)
TR (1) TR200301208T2 (enExample)
UA (2) UA82983C2 (enExample)
WO (1) WO2002060929A2 (enExample)
ZA (1) ZA200305733B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
JP4259868B2 (ja) * 2001-02-01 2009-04-30 バイオジェン・アイデック・エムエイ・インコーポレイテッド ニューブラスチンのポリマー結合体および同様の使用方法。
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
ES2374971T3 (es) * 2001-03-28 2012-02-23 Biogen Idec Ma Inc. Uso de polipéptidos de neublastina para el tratamiento del dolor neuropático.
PT3025726T (pt) * 2002-01-18 2020-01-09 Biogen Ma Inc Compostos do polímero polialquileno e utilizações dos mesmos
JP4742025B2 (ja) 2003-01-31 2011-08-10 バイオジェン・アイデック・エムエイ・インコーポレイテッド 変異ニューブラスチンのポリマー結合体
EP1897552B1 (en) 2003-04-18 2009-06-17 Biogen Idec MA Inc. Polymer-conjugated glycosylated neublastin
AU2004245175C1 (en) * 2003-06-10 2010-03-18 Biogen Ma Inc. Improved secretion of neublastin
US7598059B2 (en) 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
CN101043899B (zh) * 2004-08-19 2011-03-30 比奥根艾迪克Ma公司 重折叠转化型生长因子beta家族蛋白
DK1786454T3 (da) * 2004-08-19 2010-09-06 Biogen Idec Inc Neublastinvarianter
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
US20100056440A1 (en) * 2006-03-01 2010-03-04 Biogen Idec Ma Inc. Compositions and methods for administering gdnf ligand family proteins
JP2010503630A (ja) 2006-09-15 2010-02-04 クレアビリス・セラピューティクス・エスピーエー ＨＭＧＢ１のＢｏｘ−ＡおよびＨＭＧＢ１のＢｏｘ−Ａ変異体のポリマー複合体
TWI445544B (zh) 2007-05-01 2014-07-21 Biogen Idec Inc 增進血管形成之組合物及方法
KR20140091721A (ko) * 2011-11-02 2014-07-22 제넨테크, 인크. 오버로드 및 용리 크로마토그래피
RU2488635C1 (ru) * 2012-03-22 2013-07-27 Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития Способ получения рекомбинантного антиангиогенного полипептида

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
WO1999043813A1 (en) * 1998-02-27 1999-09-02 Regeneron Pharmaceuticals, Inc. Modified ciliary neurotrophic factor, method of making and methods of use thereof
WO2000001815A2 (en) * 1998-07-06 2000-01-13 Nsgene A/S Neurotrophic factors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034475A2 (en) * 1998-12-09 2000-06-15 Amgen Inc. Grnf4, a gdnf-related neurotrophic factor
JP4259868B2 (ja) * 2001-02-01 2009-04-30 バイオジェン・アイデック・エムエイ・インコーポレイテッド ニューブラスチンのポリマー結合体および同様の使用方法。

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
WO1999043813A1 (en) * 1998-02-27 1999-09-02 Regeneron Pharmaceuticals, Inc. Modified ciliary neurotrophic factor, method of making and methods of use thereof
WO2000001815A2 (en) * 1998-07-06 2000-01-13 Nsgene A/S Neurotrophic factors

Also Published As

Publication number Publication date
PT1355936E (pt) 2007-09-28
PL211162B1 (pl) 2012-04-30
KR20080098662A (ko) 2008-11-11
ATE365748T1 (de) 2007-07-15
SG149685A1 (en) 2009-02-27
NZ527863A (en) 2006-09-29
NO332150B1 (no) 2012-07-09
UA82983C2 (ru) 2008-06-10
JP4259868B2 (ja) 2009-04-30
AR035077A1 (es) 2004-04-14
AU2002247037B2 (en) 2007-08-16
KR100872807B1 (ko) 2008-12-09
EE05537B1 (et) 2012-04-16
GEP20063916B (en) 2006-09-11
DE60220879T2 (de) 2008-03-06
JP4423338B2 (ja) 2010-03-03
KR20030074766A (ko) 2003-09-19
HU228973B1 (en) 2013-07-29
MY143685A (en) 2011-06-30
EP1355936B1 (en) 2007-06-27
NO20033441L (no) 2003-10-01
MXPA03006805A (es) 2003-11-13
SK9712003A3 (en) 2004-01-08
IS6879A (is) 2003-07-17
EP1355936A2 (en) 2003-10-29
UA100967C2 (ru) 2013-02-25
CA2436407C (en) 2011-08-30
HUP0500637A2 (hu) 2005-09-28
CY1106886T1 (el) 2012-09-26
EE200300355A (et) 2003-10-15
ES2289091T3 (es) 2008-02-01
PL372101A1 (en) 2005-07-11
NO20033441D0 (no) 2003-08-01
DK1355936T3 (da) 2007-10-29
RS50857B (sr) 2010-08-31
IL156941A (en) 2008-11-03
BG66393B1 (bg) 2013-11-29
JP2005503763A (ja) 2005-02-10
ZA200305733B (en) 2005-02-23
WO2002060929A3 (en) 2003-03-06
DE60220879D1 (de) 2007-08-09
EP1862475A1 (en) 2007-12-05
JP2009039135A (ja) 2009-02-26
CZ20032080A3 (cs) 2003-10-15
HK1057759A1 (en) 2004-04-16
BR0206852A (pt) 2005-05-03
WO2002060929A2 (en) 2002-08-08
EA009771B1 (ru) 2008-04-28
IS2867B (is) 2014-02-15
CA2436407A1 (en) 2002-08-08
KR100960063B1 (ko) 2010-05-31
BG108111A (bg) 2004-12-30
SI1355936T1 (sl) 2007-12-31
YU61003A (sh) 2006-05-25
EA200300852A1 (ru) 2004-06-24
SK288123B6 (sk) 2013-09-03
HUP0500637A3 (en) 2010-01-28
TR200301208T2 (tr) 2005-05-23
CN1500095A (zh) 2004-05-26
IL156941A0 (en) 2004-02-08

Similar Documents

Publication Publication Date Title
JP4423338B2 (ja) ニューブラスチンのポリマー結合体および同様の使用方法。
US8119114B2 (en) Polymer conjugates of mutated neublastin
AU2002247037A1 (en) Polymer conjugates of neublastin and methods of using same
RS61003B1 (sr) Postupak za kontrolu koncentracije hi u toku ostatka
KR101293805B1 (ko) 돌연변이된 뉴블라스틴의 중합체 컨주게이트
HK1057759B (en) Polymer conjugates of neublastin and methods of using same
HK1115142A (en) Polymer conjugates of neublastin and methods of using same
HK1156051A (en) Polymer conjugates of mutated neublastin
HK1085663B (en) Mutated neublastin

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: BIOGEN MA INC.

Free format text: FORMER NAME: BIOGEN IDEC MA

CP01 Change in the name or title of a patent holder

Address after: Massachusetts, USA

Patentee after: Than Ao Gen MA company

Address before: Massachusetts, USA

Patentee before: Biogen Idec MA Inc.

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100616

Termination date: 20160125

EXPY Termination of patent right or utility model